Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AREN0321||COG||Treatment of High Risk Renal Tumors: A Groupwide Phase II Study||Pediatric CIRB||Available to Open|
|AOST1421||COG||A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab; NSC# 764038; IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma||Pediatric CIRB||Available to Open|
|NRG-GY018||NRG||A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-49907||CALGB||A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens; Cyclophosphamide; Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC); Versus Capecitabine in Women 65 Years and Older with Node Positive or Node Negative Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1A05||ECOG||Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) - Lenalidomide (Revlimid) - Dexamethasone (VRD) versus Bortezomib (Velcade) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031102||Alliance||A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel; Ifosfamide; and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA3163||ECOG-ACRIN||Phase II Randomized Trial of Neo-Adjuvant Chemotherapy followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA9171||Alliance||Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|9149||ETCTN||Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0924||RTOG||Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial||Adult CIRB - Late Phase Emphasis||Available to Open|